Atypical Hemolytic Uremic Syndrome market Forecast. DelveInsight's Atypical Hemolytic Uremic Syndrome Market report offers an in-depth understanding of the ...

Bracing for a federal funding drought and higher state costs for Medicare and Medicaid, Gov. Ned Lamont urged pharma ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...

Monopar Therapeutics Inc . (NASDAQ:MNPR) stock soared to a 52-week high, reaching a price level of $38.91. According to ...

Alzheimer's disease Therapeutics Market. LAS VEGAS, NV, UNITED STATES, January 23, 2025 /EINPresswire / -- DelveInsight's“Acute Respiratory Distress Synd ...

Orphan Drugs Market Orphan Drugs Market Dublin, Jan. 22, 2025 (GLOBE NEWSWIRE) -- The "Orphan Drugs - Global Strategic ...

Efzimfotase alfa is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Hypophosphatasia. According to GlobalData, Phase III drugs for Hypophosphatasia have a 100% ...

Takeda opens its first Innovation Capability Centre in Bengaluru, targeting to hire 750 professionals in AI, data science, and cybersecurity. The facility aims to advance AI in drug discovery, ...

CEOs of some of the largest drugmakers said this week they were encouraged after Trump said at a meeting with pharma executives late last year that these middlemen need to be eliminated.

The Impact of the US Biosecure Act on Global Pharma Manufacturing The US Biosecure Act has significant implications for the global pharmaceutical supply chain. By restricting Chinese companies ...

Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

Alexion Pharmaceuticals (NASDAQ: ALXN) is a US-headquartered biopharmaceutical company focused on developing and delivering therapies for patients with severe and life-threatening diseases. Alexion ...